Q81.1 Epidermolysis bullosa letalis

Name of the Condition

• Epidermolysis bullosa letalis

Summary

Epidermolysis bullosa letalis is a severe, often fatal, congenital skin disorder characterized by extreme skin fragility and blister formation. It results from genetic mutations affecting proteins essential for skin adhesion, leading to widespread blistering and tissue damage. The condition typically presents at birth or shortly after, with significant morbidity due to skin and mucosal involvement.

Causes

Epidermolysis bullosa letalis is caused by mutations in genes encoding structural proteins in the skin, such as keratin 14 (KRT14) or collagen VII (COL7A1). These mutations disrupt the integrity of the dermal-epidermal junction, leading to spontaneous or trauma-induced blistering. Inheritance is usually autosomal recessive, though rare autosomal dominant cases may occur.

Risk Factors

• Family history of epidermolysis bullosa or related skin disorders.
• Consanguinity (parents who are blood relatives).
• Genetic predisposition to mutations in skin structural proteins.

Symptoms

• Widespread blistering of the skin and mucous membranes at birth.
• Erosions and ulcerations from minor trauma or friction.
• Nail dystrophy or loss.
• Scarring and contractures as lesions heal.
• Potential involvement of internal organs (e.g., esophagus, respiratory tract).

Diagnosis

Diagnosis is confirmed through clinical evaluation, skin biopsy, and immunofluorescence mapping or genetic testing. Biopsy samples are analyzed to identify the level of skin separation (e.g., within the basement membrane zone) and specific protein deficiencies. Genetic testing identifies mutations in associated genes, aiding in prognosis and family counseling.

Treatment Options

Management focuses on wound care, pain control, and preventing infection. Topical and systemic therapies may include antibiotics, analgesics, and dressings to protect fragile skin. Nutritional support and monitoring for complications (e.g., sepsis, respiratory issues) are critical. Experimental therapies, such as gene therapy, are under investigation.

Prognosis and Follow-Up

Prognosis is poor, with many affected infants succumbing to sepsis or respiratory failure in the neonatal period. Survivors require lifelong multidisciplinary care, including dermatology, nutrition, and physical therapy. Regular follow-up is essential to manage complications and adjust treatment plans.

Complications

• Severe infections (e.g., sepsis) from open wounds.
• Respiratory distress due to airway or lung involvement.
• Nutritional deficiencies from oral blistering.
• Contractures and mobility limitations from scarring.
• Psychological impact due to chronic pain and disfigurement.

Lifestyle & Prevention

• Gentle handling of skin to avoid trauma.
• Use of soft clothing and non-adhesive dressings.
• Maintaining a cool environment to reduce sweating and friction.
• Genetic counseling for families with a history of the condition.

When to Seek Professional Help

Seek immediate medical attention for signs of infection (e.g., fever, increased pain, pus), respiratory distress, or failure to thrive. Consult a dermatologist or geneticist for diagnosis and management of new or worsening symptoms.

Tips for Medical Coders

Document the extent of skin and mucosal involvement, presence of systemic complications, and any genetic testing results. Ensure coding reflects the severity and specific subtype (e.g., junctional epidermolysis bullosa letalis) when supported by clinical documentation. Note associated conditions, such as infections or respiratory issues, for comprehensive coding.